Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Access to AP01 (pirfenidone solution for inhalation) in progressive fibrosing interstitial lung diseases
2020-005103-39Phase 2Active
- Sponsor
- Avalyn Pharma, Inc.
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pirfenidone in interstitial lung disease (ILD), idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), sponsored by Avalyn Pharma, Inc. Primary endpoint: Access to AP01 therapy. Started Dec 2020; status: active.
02
Drugs
pirfenidone
03
Conditions
interstitial lung disease (ILD)idiopathic pulmonary fibrosis (IPF)progressive pulmonary fibrosis (PPF)
Beyond the preview
Go deeper on 2020-005103-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005103-39.